Immuno-Oncology DOAJ Verified

Immuno-Oncology Print: 3105-6628 Online: 3105-6636 CODEN: MZABB7 Code Assignment: Chemical Abstracts Service (CAS), USA Distribution Support: China International Book Trading Corporation (CIBTC) Import Record Number: G015Z129 Publication Model: Gold Open Access (Gold OA) under the CC BY 4.0 license, with full-text permanent free access. Publisher: Macau Sino-Foreign Medical Publishing Limited Publication Frequency: Bimonthly Languages: Chinese, English Submission Requirement: Chinese submissions are accepted (English title, abstract, keywords, author affiliations and names must be provided simultaneously). This journal has been indexed by multiple authoritative academic databases worldwide. It is committed to promoting the global dissemination of high-quality research and collaborating with scholars worldwide to build an open, collaborative and forward-looking international academic community. Core Positioning Immuno-Oncology is an authoritative academic journal focusing on cutting-edge basic research and clinical translational innovation in tumor immunology. The journal is dedicated to systematically advancing theoretical breakthroughs and technological innovations in cancer immunotherapy, with emphasis on core scientific issues including the regulatory mechanisms of immune checkpoints, dynamic remodeling of the tumor microenvironment, innovative cell therapy technologies, and the development of precise biomarkers. We strongly advocate an interdisciplinary and integrated research paradigm, integrating advanced methodologies from immunology, oncology, molecular medicine and computational biology, aiming to provide solid theoretical support and innovative solutions for the clinical practice of cancer immunotherapy. Scope The journal focuses on the following cutting-edge research areas: Molecular mechanisms and resistance evolution of immune checkpoint inhibitors Innovative optimization and clinical translation of next-generation cell therapy technologies such as CAR-T/NK/TCR-T Analysis of spatiotemporal dynamic regulatory networks in the tumor immune microenvironment Tumor neoantigen screening systems and personalized immunotherapy strategies Systematic discovery and clinical validation of biomarkers for immunotherapy response/resistance Molecular mechanisms and precision management of immunotherapy-related adverse events Novel tumor vaccine design and innovative combination therapy strategies Interaction mechanisms between microbiome and tumor immune response Spatiotemporal synergistic effects of radiotherapy and immunotherapy Immunotherapy clinical trial design and real-world evidence system establishment Academic Recruitment We are now globally seeking: Editorial Board Members / Associate Editors / Peer Reviewers / Editor-in-Chief Outstanding scholars in the field of immuno-oncology are invited to join our academic community and jointly lead the development of the discipline. Aims and Vision The journal aims to build a globally influential academic hub for immuno-oncology, accelerating the translation of basic research discoveries into clinical therapeutic paradigms. We are committed to establishing an open and collaborative international academic network, building a high-level dialogue platform for global researchers, clinical experts and industrial innovators, and continuously promoting paradigm innovation in the field of cancer immunotherapy, ultimately benefiting human health.